We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rare Variants Associated with Blood Pressure Regulation

By LabMedica International staff writers
Posted on 07 Dec 2020
Genes likely play some role in high blood pressure, heart disease, and other related conditions. More...
However, it is also likely that people with a family history of high blood pressure share common environmental and other potential factors that increase their risk.

High blood pressure, or hypertension, is a common disease in which blood flows through blood vessels at higher than normal pressures. A high force of blood flow can damage and weaken the blood vessels. Over time, hypertension can harm different organs, including the heart, kidneys, brain, and eyes.

A team of scientists at the University of Cambridge (Cambridge, UK) and their colleagues used exome and genotyping arrays for up to 1.3 million individuals of European, African American, South Asian, or Hispanic ancestry enrolled in the large projects such as UK Biobank (UKBB) or in dozens of smaller studies. The team searched for rare variants involved in four main blood pressure-related traits: hypertension, inverse-normal transformed systolic blood pressure, diastolic blood pressure, or pulse pressure. The team relied on exome array-wide association (EAWAS) and rare variant-focused genome-wide association (RV-GWAS) studies and meta-analyses, along with fine-mapping and gene-based analyses, to search for rare variants linked to the blood pressure traits in question.

The investigators found 106 previously undetected loci linked to blood pressure, and dozens of blood pressure-related rare variants, while highlighting enhanced effects for individual rare variants compared to the 1,000 or more common, small effect variants implicated in blood pressure in the past. Just two new loci, in or around the RP11 or VTN genes, had genome-wide significant ties to all of the blood pressure traits considered. Average effects of rare variants were around eight times larger than common variant effects and indicate potential candidate causal genes at new and known loci (for example, GATA5 and PLCB3).

Along with rare variants falling at genes or loci already known to contribute to blood pressure regulation, the team's analysis of common and rare blood pressure-related variants from the new analysis and from studies done before led to active chromatin regions involved in the fetal development of blood vessels, heart, muscle, and other tissues or organs. It also saw genes with potential ties to congenital heart defects, as well as genes with enhanced gene expression during heart development.

Joanna M. M. Howson, PhD, a cardiovascular epidemiologist and a corresponding author of the study, said, “The results from our study indicate rare blood pressure associated variants contribute to blood pressure variability in the general population, and their identification has provided information on new candidate genes and potential causal pathways.” The study was published on November 23, 2020 in the journal Nature Genetics.

Related Links:
University of Cambridge


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.